Results 1 to 10 of about 118,635,816 (237)

Acquired Hemophilia A Presenting as Intramuscular Hematoma

Journal of Investigative Medicine High Impact Case Reports, 2018
Acquired hemophilia A poses a clinical and diagnostic challenge. Although rare, it is still the most common acquired factor deficiency. We present a case of acquired hemophilia A diagnosed in a 71-year-old female who presented with a right thigh hematoma
Ghassan Al-Shbool, Anusha Vakiti
exaly   +3 more sources

Acquired hemophilia A and plasma cell neoplasms: a case report and review of the literature [PDF]

Journal of Medical Case Reports, 2020
Background Acquired hemophilia A is a rare autoimmune disease with clinically often significant bleeding diathesis resulting from circulating autoantibodies inhibiting coagulation factor VIII.
Katarzyna A. Jalowiec, Martin Andres, Behrouz Mansouri Taleghani, Albulena Musa, Martina Dickenmann, Anne Angelillo-Scherrer, Alicia Rovó, Johanna A. Kremer Hovinga   +7 more
doaj   +3 more sources

Acquired Hemophilia A Secondary to an Immune Checkpoint Inhibitor: A Case Report

JTO Clinical and Research Reports, 2022
We report a case of a patient with extensive-stage SCLC who developed acquired hemophilia A during maintenance atezolizumab therapy. The patient initially presented with asymptomatic anemia, a prolonged acquired prothrombin time, and factor VIII (FVIII ...
James Fletcher, MBBS, Robert Bird, MBBS, Andrew J.W. McLean, MBBS, Kenneth O’Byrne, MD, Wen Xu, MBBS   +4 more
doaj   +2 more sources

Clinical Experience with Emicizumab and Rituximab as First-Line Treatment in a Case Series of Acquired Hemophilia A. [PDF]

Hematol Rep
Background: Acquired hemophilia A (AHA) is a bleeding disorder caused by autoantibodies against coagulation factor VIII. Treatment includes controlling bleeding and eliminating the inhibitor.
Ota H, Yasuda K, Toyota N, Masuoka K.
europepmc   +2 more sources

Emicizumab in the treatment of acquired hemophilia A: A Two-Center experience. [PDF]

Ann Hematol
Emicizumab is a FVIII mimetic antibody used in the treatment of inherited hemophilia A that could potentially be used in acquired hemophilia A (AHA) to achieve hemostasis and shorten hospital stay while reducing bypass therapies. We report on 12 cases of
Su M, Yates S, Sanchez M, Shen YM.
europepmc   +2 more sources

Postpartum acquired hemophilia presenting as compartment syndrome: a diagnostic challenge in the emergency department. [PDF]

Int J Emerg Med
Background Acquired hemophilia A is an uncommon but potentially life-threatening bleeding disorder caused by autoantibodies against factor VIII. It can be associated with autoimmune disease, malignancy, or pregnancy. Case report We describe a 31-year-old
Mujahed W, Nama A, Kalish J, Nimer Q, Hahn B, Alpert EA.   +5 more
europepmc   +2 more sources

Acquired hemophilia A: a case report and review of the literature. [PDF]

J Med Case Rep
Background Acquired hemophilia A is a rare autoimmune disease characterized by inhibitory antibodies against coagulation factor VIII, leading to an increased risk of bleeding. The relevance of this case lies in its high associated morbidity and mortality,
Perotti-Abad JA, Cabezas-Corado Á, Astolfi-Labrador L, Baus-Domínguez M, Machuca-Portillo G, Serrera-Figallo MÁ, Torres-Lagares D.   +6 more
europepmc   +2 more sources

Surgery-associated acquired hemophilia A: a report of 2 cases and review of literature

BMC Surgery, 2020
Background Acquired Hemophilia A (AHA) is a rare bleeding diathesis in patients with no previous personal or family bleeding history. The diagnosis of this disease often delays due to unfamiliarity of physicians with it, which leads to its high mortality
Umar Zeb Khan, Xiangwu Yang, Matiullah Masroor, Abdul Aziz, Hui Yi, Hai Liu   +5 more
doaj   +1 more source

A Rare Case of Acquired Hemophilia A in Adolescents and Young Adults

Clinical Pediatric Hematology-Oncology, 2022
Acquired hemophilia A (AHA) is a rare bleeding disorder, especially in adolescents and young adults (AYAs) attributable to the development of autoantibodies against coagulation factor VIII (FVIII). AHA diagnosis is difficult; patients lack any history of
Min Jeong Lee, Young Shil Park
doaj   +1 more source

Acquired hemophilia A treated with rituximab in a 62-year-old female with rheumatoid arthritis: a case-based review

Reumatismo, 2023
Acquired hemophilia A (AHA) is a rare autoimmune disorder with unpredictable hemostasis that is caused by autoantibody formation against coagulation factor VIII. AHA can occur in the context of autoimmune inflammatory rheumatic disorders. Here we report
D. Mohamadzadeh, S. Assar, F. Farsad
doaj   +1 more source